BRAF and melanoma: The phase III COMBI-AD trial30 included patients with resected AJCC7 stage III (SLN >1 mm) melanoma with BRAF V600E or V600K mutations who were randomised to receive either 12 months of adjuvant dabrafenib–trametinib or placebo.